



Atty. Dkt. No. 018733-0967

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: David M. GOLDENBERG et al.

Title: IMMUNOTHERAPY OF  
AUTOIMMUNE DISORDERS  
USING ANTI-CD22 ANTIBODIES

Appl. No.: 09/590,284

Filing Date: 06/09/2000

Examiner: J. Roark

Art Unit: 1644

**AMENDMENT TRANSMITTAL**

Commissioner for Patents  
Washington, D.C. 20231

**RECEIVED**

JUN 24 2002

TECH CENTER 1600/2000

Sir:

Transmitted herewith is an amendment in the above-identified application.

- ☐ Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a Small Entity statement previously submitted.
- ☐ Small Entity statement is enclosed.
- ☒ The fee required for additional claims is calculated below:

	Claims as Amended	Previously Paid For	Extra Claims Present	Rate	Additional Claims Fee
Total Claims:	38	36	2	x \$18.00	\$36.00
Independents:	2	3	0	x \$84.00	\$0.00
First presentation of any Multiple Dependent Claims:				+ \$280.00	\$0.00
CLAIMS FEE TOTAL:					\$36.00

- ☒ Applicant hereby petitions for an extension of time under 37 C.F.R. § 1.136(a) for the total number of months checked below:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David M. GOLDENBERG *et al.*

Title: IMMUNOTHERAPY OF  
AUTOIMMUNE DISORDERS  
USING ANTI-CD22  
ANTIBODIES WHICH TARGET  
B-CELLS

Appl. No.: 09/590,284

Filing Date: June 9, 2000

Examiner: J. Roark

Art Unit: 1644

ELECTION OF SPECIES

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In reply to the communication dated April 15, 2002, applicants now provide a more detailed election of species, as requested. In addition, applicants request entry into the record of the following new claims:

RECEIVED

In the claims

JUN 24 2002

37. (New) A method of treating multiple sclerosis, comprising administering to a subject with multiple sclerosis a therapeutic composition comprising a naked anti-CD20 antibody, a naked anti-CD22 antibody that binds with epitope B of the CD22 antigen, and a cytokine, wherein the two antibodies and the cytokine can be administered concurrently or in any order.

38. (New) A method according to claim 36, wherein the cytokine is IFN- $\beta$ .

10/20/2002 11:00AM: 09/590,284

10/20/2002

10/20/2002

#15/A  
gnd  
6/27/02

